Volitionrx (VNRX) Liabilities and Shareholders Equity (2011 - 2025)

Volitionrx has reported Liabilities and Shareholders Equity for 11 years, with the latest figure at $6.9 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 26.58% year-over-year to $6.9 million; the trailing twelve-month figure through Dec 2025 stood at $30.6 million (down 43.98% YoY), and the FY2025 full-year result was $6.9 million, down 26.58% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $6.9 million, up from $6.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $35.2 million in Q2 2021, with the low at $6.4 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $19.3 million across 5 years, with a median of $18.3 million in 2022.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 52.78% — and 2024, when it slumped 66.37%.
• Volitionrx's Liabilities and Shareholders Equity stood at $27.5 million in 2021, then slumped by 33.45% to $18.3 million in 2022, then surged by 52.78% to $28.0 million in 2023, then plunged by 66.37% to $9.4 million in 2024, then dropped by 26.58% to $6.9 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $6.9 million (Q4 2025), $6.4 million (Q3 2025), and $8.7 million (Q2 2025), per Business Quant data.